Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study

Abstract Aims/Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) might be less effective in patients with severe hyperglycemia, because hyperglycemia downregulated the GLP‐1 receptor in an animal study. To examine this hypothesis clinically, we compared the glucose‐lowering effects of...

Full description

Bibliographic Details
Main Authors: Yumie Takeshita, Yuki Kita, Takeo Tanaka, Hisanori Goto, Yujiro Nakano, Chisato Teramura, Yasufumi Enyama, Toshinari Takamura, the Establishment of Rationale for Antiaging Diabetic Medicine (ERA‐DM) Study Group
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Journal of Diabetes Investigation
Subjects:
Glucagon‐like peptide‐1 receptor agonists
Glucose toxicity
Insulin–glucagon‐like peptide‐1 receptor agonist relay regimen
Online Access:https://doi.org/10.1111/jdi.13749

Internet

https://doi.org/10.1111/jdi.13749

Similar Items